What Sigachi does

Sigachi Industries Limited, founded in 1989 in Hyderabad and publicly listed on BSE/NSE since 2021 (ticker: SIGACHI), is a vertically integrated Indian manufacturer of pharmaceutical excipients, Active Pharmaceutical Ingredients (APIs), food and nutrition additives, and cosmetic ingredients, with a parallel Operations & Maintenance (O&M) services line for chemical, petrochemical, fertilizer, and energy plants. Its core technical platform centres on Microcrystalline Cellulose (MCC) manufacturing — branded as HiCel™ (spray-dried directly compressible grades) and AceCel® (non-spray-dried grades for wet granulation) — extended into co-processed excipients (BARETab® PH/ODT/Nutra, HiCel™ HFS/CE15/SMCC), ready-mix film coatings (PureCoat®), sustained-release polymer blends (UltraMod™ SR), superdisintegrants (Stargel®, HiLose™), and lubricants (MagLub®, FloLub™). Two DSIR-accredited R&D centres support new molecule development, and the company runs five manufacturing facilities across Telangana, Gujarat, and Karnataka with combined capacity of 21,700 MTPA.

The business model is sales-led B2B, selling through direct enterprise sales teams in India, wholly-owned subsidiaries Sigachi US Inc. and Sigachi MENA FZCO in the Americas and Middle East, and channel partners across 65+ countries; approximately 60% of output is exported into highly regulated markets (US, Europe, Australia) where USFDA, EDQM CEP, EXCiPACT GMP, WHO-GMP, HACCP, ISO 9001/14001/45001 certifications act as entry barriers. Pricing is quote-based and negotiated under multi-year contracts. Revenue is generated across four streams: pharmaceutical excipients (the core, including binders, disintegrants, coatings, lubricants, carriers), APIs (9 products including Pregabalin, Ritonavir, Metformin, Atorvastatin — 15% of revenue after the August 2023 acquisition of 80% of Trimax Bio Sciences for Rs 100 crore), food/nutrition premixes (Joymix®, AceFibre®), cosmetic ingredients (CosmoCel™ under ECOCERT/COSMOS certification), and consulting-based O&M services for large Indian industrial operators including GACL, OPAL, Aditya Birla, Adani, GNFC, NPCIL, and GAIL.

The company is currently navigating a major operational and reputational shock: a June 30, 2025 explosion at its Pashamylaram (Hyderabad) unit killed 54 workers — the deadliest incident in India's pharmaceutical sector — leading to a 90-day production suspension, culpable homicide proceedings, and the December 2025 arrest of CEO Amit Raj Sinha (granted bail by the Telangana High Court in February 2026). FY26 revenue declined 2.13% to Rs 477.83 crore and Q1 FY27 fell 5.4% YoY, while the company has simultaneously announced a Rs 1.5 billion Gujarat expansion, a Cystic Fibrosis API pipeline (Vanzacaftor, Tezacaftor, Deutivacaftor) targeting Rs 250 crore/year from Q4 FY27 with Vanzacaftor patent protection to 2039, and an August 2026 preferential issue of equity or convertible securities.

Name

Sigachi

Legal name

Sigachi Industries Limited

Website

https://sigachi.com

Company type

Public

Founded year

1989

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Sigachi Industries Limited, founded 1989 in Hyderabad and listed since 2021, manufactures microcrystalline cellulose excipients, APIs, food/nutrition and cosmetic ingredients for global pharmaceutical and industrial buyers, with a parallel O&M services business for large Indian chemical and energy operators.

Ownership category

akta.pro rank

Product category

Pharmaceutical Excipients & Ingredients

NAICS

Chemical Manufacturing (325), Pharmaceutical and Medicine Manufacturing (3254), Food Manufacturing (311)

SIC

Industrial Organic Chemicals (2860), Plastic Material, Synth Resin/Rubber, Cellulos (No Glass) (2820), Chemicals & Allied Products (2800)

akta.pro primary industry

Nanocellulose & Cellulose Derivatives (CNC/CNF, MCC, ethers/esters) (IMAMALAD)

akta.pro secondary industries

Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines) (HLAGAGAI), Bio-based Materials & Fibers (e.g., cellulose derivatives, lignin-based materials, nanocellulose) (EUAAAIAD)

Keywords

• Pharmaceutical excipients
• Microcrystalline cellulose
• Active pharmaceutical ingredients
• Tablet formulation ingredients
• Pharmaceutical manufacturing

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Excipients: Primary revenue driver including Microcrystalline Cellulose (MCC), pre-formulated excipients, high functionality excipients, thickeners, stabilizers, film coatings, binders, lubricants, carriers, and superdisintegrants for pharmaceutical tablet manufacturing
2. Active Pharmaceutical Ingredients (API): Revenue contribution doubled to 15% following Trimax Bio Sciences acquisition; includes 9 API products and intermediates for anti-ulcers, antivirals, cardiovascular, and other therapeutic categories
3. Food & Nutrition Products: Ready-to-use additives, stabilisers, dietary fibre products for food processing industry including Joymix brand premixes
4. Cosmetic Ingredients: CosmoCel product line for skincare, haircare, and toiletry applications with ECOCERT/COSMOS certification
5. Operations & Maintenance Services: Consulting-based O&M services for chemical, petrochemical, pharmaceutical, fertilizer plants, and solar PV operations across India

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Sigachi Industries manufactures and supplies microcrystalline cellulose (MCC) and a broad portfolio of pharmaceutical excipients — including binders, superdisintegrants, lubricants, carriers, film coatings, polymer blends, and pre-formulated co-processed excipients — alongside active pharmaceutical ingredients (APIs), food/nutrition premixes, cosmetic cellulose ingredients, and operations & maintenance services for industrial plants.

Product overview

Sigachi Industries is a diversified pharmaceutical excipients and ingredients company with a portfolio spanning Active Pharmaceutical Ingredients (APIs), Microcrystalline Cellulose (MCC) products, co-processed excipients, film coatings, and food/nutrition additives. The core products include HiCel™ and AceCel® MCC brands available in multiple grades for various manufacturing processes, complemented by specialized excipients like BARETab® (pre-formulated), HiCel™ HFS/CE15/MCG/SMCC (high functionality), and UltraMod™ SR (sustained release polymers). The PureCoat® film coating line and API portfolio (9 products including Metformin, Atorvastatin, Pregabalin) round out the pharmaceutical offerings, while food products include Joymix® premixes and AceFibre®, and cosmetic ingredients include CosmoCel™. The company also provides Operations & Maintenance services for industrial clients.

Differentiator

Problem solved

Functional benefit

Brands

• BARETab: Pre-formulated co-processed excipient brand for continuous tablet manufacturing, including BARETab PH, BARETab ODT, and BARETab Nutra variants.
• HiCel
• AceCel
• PureCoat
• UltraMod
• MagLub
• FloLub
• Joymix
• CosmoCel
• GloCel
• CoatCel
• Stargel
• HiLose

Products and services

• Active Pharmaceutical Ingredients (APIs)
• HiCel™ Microcrystalline Cellulose (MCC)
• AceCel® Microcrystalline Cellulose
• BARETab® Pre-Formulated Co-Processed Excipients
• PureCoat® Film Coating Systems
• UltraMod™ SR Polymer Blends
• Stargel® Superdisintegrant
• HiLose™ Superdisintegrant
• MagLub® Lubricant
• FloLub™ Lubricant
• Puretalc™ Pharmaceutical Carrier
• HiCel™ MCC Spheres
• Joymix® Food Premixes
• AceFibre® Dietary Fibre
• CosmoCel™ Cosmetic Ingredients
• GloCel® Welding Cellulose
• CoatCel® Filter Aid Cellulose
• Operations and Maintenance (O&M) Services

Quantifiable outcome

• 60% of products exported to highly regulated markets
• +2 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Six partnerships are on record, tiered strategic and core.

• Indian NavystrategicStrategic or Co-development Partner · 13 March 2025MOU signed for collaboration with Indian Navy, announced in March 2025, representing strategic engagement in government/defense sector.
• JV FormationstrategicStrategic or Co-development Partner · 19 October 2023Announcement of joint venture formation in October 2023, expanding strategic partnerships and market reach.
• Trimax Bio Sciences Private LimitedcoreStrategic or Co-development Partner · 10 August 2023Sigachi acquired 80% stake in Trimax Bio Sciences for Rs 100 crore (INR 1 billion) in August 2023, with call option to purchase remaining 20% after three years for up to Rs 25 crore. Trimax is a USFDA, EMEA, and WHO-GMP certified API manufacturer expanding Sigachi's capabilities in pharmaceutical ingredients. Located in Raichur, Karnataka.
• NIPER (National Institute of Pharmaceutical Education and Research)strategicStrategic or Co-development Partner · 15 December 2021MOU signed for research and development collaboration with NIPER, India's premier pharmaceutical research institute, announced December 2021.
• Sigachi US Inc.coreOthersWholly-owned subsidiary established in the Americas region for sales, marketing, and customer support operations. Located at Monroe Township, New Jersey, USA.
• Sigachi MENA FZCOcoreOthersWholly-owned subsidiary for Middle East and North Africa market operations. Located in Dubai Silicon Oasis, UAE.

Scale indicators15 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• Roquette: French specialty starch and polyol producer with pharmaceutical excipient portfolio including MCC and pre-formulated platforms. Comparable supplier to global pharma formulators and overlapping in binders, fillers, and co-processed excipients.
• DFE Pharma: Dutch-headquartered excipient supplier offering MCC, superdisintegrants, and specialty excipients for solid oral dosage forms. Direct competitor to Sigachi in regulated pharma excipient markets across Europe and globally.
• Asahi Kasei: Japanese chemical manufacturer selling Ceolus® brand MCC, a leading specialty cellulose for direct compression. Comparable in product technology and target customers for high-functionality excipients.
• JRS Pharma (J. Rettenmaier & Söhne): German-headquartered global leader in MCC and cellulose-based pharmaceutical excipients with the VIVAPUR® and EMCOCEL® brands. Closest direct competitor to Sigachi's HiCel™ MCC portfolio in tablet binder applications.
• Colorcon: US-based leader in film coating systems and modified-release excipients. Directly competes with Sigachi's PureCoat® film coating and UltraMod™ polymer blend product categories for oral solid dose formulators.
• Mingtai Chemical: Taiwanese MCC and cellulose derivative manufacturer serving pharmaceutical and food customers globally. Direct competitor in commodity and specialty MCC grades, particularly across Asian regulated markets.
• Anhui Sunhere Pharmaceutical Excipients: Chinese manufacturer of pharmaceutical excipients including MCC, starch derivatives, and superdisintegrants. Comparable Asian cost-competitive peer targeting similar formulation customers as Sigachi.
• DuPont/MFC (now IFF): Former FMC BioPolymer business now under IFF, producing MCC under brands such as Avicel®. Direct competitor in pharmaceutical-grade MCC across global regulated markets, overlapping with Sigachi's core product line.

Broad incumbents

• BASF: Global chemical giant with pharmaceutical excipients and API portfolio across binders, disintegrants, and coatings. Broader incumbent offering overlapping products within a much wider specialty chemicals portfolio rather than specializing in cellulose excipients.
• Evonik: German specialty chemicals company with pharmaceutical polymers, API, and excipient operations. Broad incumbent in regulated excipient space with overlapping capabilities though not focused on cellulose derivatives.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/SigachiL
• YouTubeyoutube.com/channel/UCV7tBse-uq9whWBHhN8aVCQ
• LinkedInlinkedin.com/company/sigachi-industries-limited/?originalSubdomain=in

Compliance16 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sigachi